GlassScriptPhysician profile
Myra Ann Irvin
NPI 1962899765
$5,013.83
in general payments reported to CMS, 2019-2025
32 companies · $725 in 2025
The $725 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $415 · 2021: $751 · 2022: $1,291 · 2023: $971 · 2024: $664 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.48 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,088.90 | 2021-2025 | |
| Novo Nordisk INC | $508.51 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $490.75 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $419.04 | 2021-2025 | |
| Amgen INC. | $369.47 | 2019-2023 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.48 | 2019-2025 | Jardiance |
| Pfizer INC. | $250.96 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $229.46 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $204.07 | 2019-2025 | |
| Axsome Therapeutics, INC. | $146.36 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.46 | 2019-2024 | Xifaxan |
| Allergan, INC. | $97.66 | 2019-2020 | |
| Astellas Pharma US INC | $84.96 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $80.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $71.91 | 2019-2025 | Airsupra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.21 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $57.14 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $47.42 | 2021 | |
| Sumitomo Pharma America, INC. | $43.63 | 2023-2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $39.72 | 2025 | Voquezna |
| Amarin Pharma, INC. | $31.23 | 2019-2020 | |
| Harmony Biosciences LLC | $29.53 | 2023 | Wakix |
| Genentech USA, INC. | $27.12 | 2019-2020 | |
| Exact Sciences Corporation | $26.70 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $22.15 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $21.02 | 2022 | |
| Corium, LLC | $18.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.29 | 2023 | Quviviq |
| Biodelivery Sciences International, INC. | $11.90 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.10 | 2021 | |
| Endogastric Solutions, INC | $9.15 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Irvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.